March 1, 2024 – Thirona is pleased to announce the activation of our IND by the FDA to allow our lead asset TBIO-101 to proceed into clinical trials. “This is obviously a major step forward in our progress” said Dr Gordon Foulkes, Thirona’s CEO. “In all the years I have been doing drug development, this is literally the first time I have ever seen a new IND where there were no adverse findings in the GLP animal toxicology studies. It’s particularly remarkable given the challenges our Industry has faced over the decades trying to develop safe ways of inhibiting TGF-β”.
The next key step is to confirm our preclinical safety translates into humans and show initial efficacy in humans. Our clinical indications for TBIO-101 include both hypertrophic and keloid scars, scleroderma and cutaneous squamous cell cancer.
THIRONA BIO, INC. CONTACTS:
Amy Conrad
(858) 914-1962
Email: amy@juniper-point.com